SBIR/STTR Research Award

AHL Hydrolase Mediated Biofilm Inhibition

Award identifier 69698cbcaecf843ce0c66a2b53fb14a45ad15277219299c5f50920a62c431875Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$133,025

Program and phase

SBIR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
LYBRADYN, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Bacterial biofilms thwart the control of nosocomial infections, such as those resulting from medical device implantation. Elevated levels of one or more quorum sensing (QS) signals have been linked to the formation of b acterial biofilms, which makes eradication of bacteria colonizing the growth-amenable surfaces of implants difficult due to their biofilm-mediated resistance to antibiotics and host defense mechanisms. Therefore, it is desirable to develop ways to control quorum sensing and thus biofilm formation of P. aeruginosa and other Gram-negative pathogens. As with many Gram-negative organisms, N-acyl homoserine lactones (AHL) function as major QS signals for P. aeruginosa, specifically N-butanoyl-l-homoserine lacton e (C(4)-HSL) and N-(3-oxododecanoyl)-l-homoserine lactone (3-oxo-C(12)-HSL). A small number of enzymes have been found that show potential for modulating QS by degrading AHLs, but there development has been limited. We have isolated enzymes from Geobacilli that possess demonstrable activity toward AHLs (functioning as lactonases) and are able to disrupt AHL-dependent processes of test organisms in liquid culture, including P. aeruginosa biofilm formation. Our most active Geobacillus enzyme, a very stable, s oluble enzyme that can be readily purified, is already being expressed in a commercially viable system. We propose to further characterize these enzymes, relative to known AHL lactonases, to judge their suitability for our ultimate objective to formulate t hese enzymes into coatings for medical device products. PUBLIC HEALTH RELEVANCE Preventing medical device-related Pseudomonas aeruginosa (PA) infections by inhibiting quorum sensing (QS) dependent processes such as biofilm formation, allowing host defense mechanisms and antibiotic strategies to be more effective, is a concept that holds great potential. Towards these ends, we discovered enzymes isolated from species of Geobacillus are capable of hydrolyzing the lactone ring of N-acyl-L- homoserine lactones, the molecular trigger of bacterial QS for Gram-negative bacteria. Furthermore, co-culturing purified these Geobacillus enzymes inhibits QS-dependent processes, such as PA biofilm formation. In Phase I, we will thoroughly characterize the lactonase activit ies of our Geobacillus enzymes. We will also quantitatively compare our Geobacillus enzymes to other emerging lactonase enzymes.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.